Physician profile
Asmi Fatima Alam
NPI 1235349044
$1,173.68
in general payments reported to CMS, 2019-2025
28 companies · $85.89 in 2025
The $85.89 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $115 · 2021: $288 · 2022: $256 · 2023: $139 · 2024: $105 · 2025: $85.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $181.18 | 2019-2025 | |
| Tris Pharma INC | $126.16 | 2020-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $115.57 | 2019-2022 | |
| Corium, LLC | $106.74 | 2022-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $102.16 | 2019-2022 | |
| Sobi, INC | $49.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.43 | 2020-2022 | |
| Neos Therapeutics, LP | $38.44 | 2019-2020 | |
| Phadia US INC. | $31.26 | 2021 | |
| Glaxosmithkline, LLC. | $27.32 | 2023 | Pediarix, Bexsero |
| Genentech USA, INC. | $26.84 | 2020-2021 | |
| Alcon Vision LLC | $25.81 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.88 | 2023 | Oxlumo |
| Shire North American Group INC | $23.74 | 2019 | |
| Sanofi Pasteur INC. | $22.76 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.44 | 2021 | |
| Seqirus USA INC | $22.23 | 2023 | Flucelvax Quadrivalent |
| Nestle Healthcare Nutrition INC. | $21.47 | 2021 | |
| Novo Nordisk INC | $21.43 | 2024 | Wegovy |
| Arbor Pharmaceuticals, INC. | $19.56 | 2019 | |
| Astellas Pharma US INC | $19.29 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.07 | 2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $17.01 | 2023 | Breztri |
| Cumberland Pharmaceuticals, INC. | $15.35 | 2023 | Kristalose |
| Lilly USA, LLC | $15.00 | 2025 | Jardiance |
| Ironshore Pharmaceuticals INC. | $13.88 | 2022 | |
| Elevate Oral Care | $12.54 | 2021 | |
| Adlon Therapeutics L.P. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asmi Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.